5-methyltetrahydrofolate and Obesity

For patients with depression, antidepressant response rates are generally low and residual symptoms can increase the risk of relapse. Poor response may be linked to increased inflammatory cytokines and obesity. Specifically targeting inflammation with adjunct l-methylfolate treatment may help patients with depression finally achieve remission. In this Webcast, experts examine the multi-directional relationship between obesity, inflammation, and depression, consider preliminary data on genetic alleles, and review evidence using l-methylfolate as a targeted therapy.

Topics: Adult; Alleles; Antidepressive Agents; Brain; Coenzymes; Controlled Clinical Trials as Topic; Cytokines; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; DNA Mutational Analysis; Drug Therapy, Combination; Genetic Predisposition to Disease; Humans; Inflammation Mediators; Lithium; Magnetic Resonance Imaging; Methylenetetrahydrofolate Reductase (NADPH2); Nerve Growth Factors; Obesity; Obesity, Abdominal; Polymorphism, Genetic; Risk Factors; Selective Serotonin Reuptake Inhibitors; Tetrahydrofolates; Waist Circumference